3. Overovanie bezpečnosti, tolerancie a efektu nalmefenu u alkoholikov

3. Overovanie bezpečnosti, tolerancie a efektu nalmefenu u alkoholikov

A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Safety, Tolerability and Efficacy Study of Nalmefene, as Needed Use, in Patients With Alcohol Dependence (2009 - 2010); sponsored by H. Lundbeck A/S

This study evaluated the long-term efficacy and safety of nalmefene treatment in reducing alcohol consumption. We randomised (1:3) 675 alcohol-dependent patients ≥ 18 years of age to 52 weeks of as-needed treatment with placebo or nalmefene 18 mg/day.